Overview
Clarithromycin is an advanced macrolide antibiotic, structurally related to erythromycin but with improved acid stability and a broader spectrum of activity. It is widely utilised for treating various respiratory tract infections, skin infections, and plays a pivotal, indispensable role as a core component in multidrug regimens aimed at eradicating Helicobacter pylori (H. pylori) to treat peptic ulcer disease.

Mechanism of Action
Similar to other macrolides, clarithromycin halts bacterial growth by penetrating the bacterial cell wall and reversibly binding to the 50S ribosomal subunit. This targeted action blocks the translocation of amino acids, thereby effectively inhibiting the synthesis of vital proteins that the bacteria require for survival and replication.

Dosage and Administration
For typical respiratory or skin infections in adults, the standard dosage is 250 mg to 500 mg taken twice daily for 7 to 14 days. When used as part of an H. pylori eradication therapy, it is usually prescribed at a dose of 500 mg twice daily in combination with a proton pump inhibitor and another antibiotic (like amoxicillin) for 10 to 14 days. It can be taken without regard to meals.

Side Effects
The most frequently encountered side effects are gastrointestinal, including nausea, vomiting, diarrhea, and abdominal pain. A very distinctive and common side effect reported by many patients is a noticeable metallic or bitter taste in the mouth. Like azithromycin, it also carries a warning for potential QT interval prolongation and cardiovascular risks.

Contraindications and Drug Interactions
Clarithromycin is a potent inhibitor of the CYP3A4 liver enzyme, leading to numerous significant drug interactions. It is strictly contraindicated for co-administration with certain statins (like simvastatin and lovastatin) due to the severe risk of muscle breakdown (rhabdomyolysis), as well as medications like colchicine in patients with renal impairment. It is also contraindicated in patients with a history of QT prolongation.

Pregnancy and Lactation
Clarithromycin is generally not recommended as a first-line agent during pregnancy, particularly in the first trimester, unless there are no alternative therapies available, due to some animal studies suggesting potential risks. It is excreted in breast milk, and caution should be exercised when administered to a nursing woman.